Skip to main content
Clinical Trials/NCT04699162
NCT04699162
Completed
Not Applicable

Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia. Experience of Two Centers in Mexico City

Christian Omar Ramos-Peñafiel, MD, PhD2 sites in 1 country56 target enrollmentJuly 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Lymphoblastic Leukemia
Sponsor
Christian Omar Ramos-Peñafiel, MD, PhD
Enrollment
56
Locations
2
Primary Endpoint
Overall survival
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The aim of this study is to describe the survival and relapses of patients with diagnosis of acute lymphoblastic leukemia at two tertiary level hospitals in the metropolitan area of the valley of Mexico

Detailed Description

Retrospective, observational study in patients with diagnosis of acute lymphoblastic leukemia, according to the criteria of the World Health Organization, from July, 2016, to October, 2020. The patients were cared for in the hematology department of the Hospital General de Mexico and in the hematology department of the Hospital Regional de Alta Especialidad Ixtapaluca. Relapse was considered in those cases with more than 5% of blasts in bone marrow and as relapse to the central nervous system with the presence of blasts in cerebrospinal fluid.

Registry
clinicaltrials.gov
Start Date
July 1, 2016
End Date
December 31, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Christian Omar Ramos-Peñafiel, MD, PhD
Responsible Party
Sponsor Investigator
Principal Investigator

Christian Omar Ramos-Peñafiel, MD, PhD

Head of the hematology hospitalization area

Hospital General de Mexico

Eligibility Criteria

Inclusion Criteria

  • Patients with diagnosis of acute lymphoblastic leukemia according to the criteria of the World Health Organization.

Exclusion Criteria

  • Age less than 15 years
  • Age over 60 years

Outcomes

Primary Outcomes

Overall survival

Time Frame: 4-years

Progression free survival

Time Frame: 4-years

Number of relapses

Time Frame: 4-years

Cases with more than 5 percent of blasts in bone marrow and as relapse to the central nervous system with the presence of blasts in cerebrospinal fluid

Study Sites (2)

Loading locations...

Similar Trials